Literature DB >> 31833466

Case Report: Cognitive Impairment without Clinical Spinal Disease May Be the First Sign of HTLV-1 Neurological Alteration.

Aline Rejane Rosa de Castro1,2, Ludimila Labanca1,2, Luciana Macedo de Resende2, Denise Utsch-Gonçalves1,2.   

Abstract

Human t-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy (HAM) is a progressive neurological disease whose diagnosis is defined by clinical manifestations and seropositivity for HTLV-1 infection. Cognitive impairment (CI) is considered to occur after spinal impairment. A 51-year-old HTLV-1-infected man classified as an asymptomatic carrier presented difficulties in listening comprehension and executive memory. He was assessed for central auditory processing (CAP), cognition (event-related auditory evoked potential [P300]), and otoneurological functions (galvanic vestibular-evoked myogenic potential [gVEMP]). Altered responses were found in CAP, P300, and gVEMP, but the neurological examination and cognitive screening were normal. After a 2-year follow-up, we disclosed a positive Babinski sign, a mild CI, worsened P300, and gVEMP latencies, and the patient reported progressive lumbar pain and difficulty running. He was, then, reclassified as HAM. The first examination, in 2016, had already shown abnormal results in P300 and gVEMP despite the HTLV-1-asymptomatic carrier status. Therefore, tests that provide subclinical measures of neurological disease progression can be useful tools for an early diagnosis and intervention in HTLV-1 patients. Electrophysiological results had worsened as well as the clinical status and the cognitive function and the progression from asymptomatic status to an HTLV-1-associated neurological disease occurred within 2 years. Thus, HTLV-1-infected individuals with complaints of CI, hearing, or otoneurological manifestations should be submitted to neuropsychological and electrophysiological tests, allowing them to be properly cared in case of HAM progression.

Entities:  

Mesh:

Year:  2020        PMID: 31833466      PMCID: PMC7008323          DOI: 10.4269/ajtmh.19-0218

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  33 in total

1.  Characterization of cognitive performance and evaluation of quality of life among patients with HTLV-1.

Authors:  Liliana Raulino Goncalves; Leopoldo Nelson Fernandes Barbosa; Paula Machado Ribeiro Magalhaes; Pedro Augusto Sampaio Rocha-Filho
Journal:  Clin Neurol Neurosurg       Date:  2017-07-12       Impact factor: 1.876

2.  Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study.

Authors:  Davi Tanajura; Néviton Castro; Paulo Oliveira; Abraão Neto; André Muniz; Natália B Carvalho; Glória Orge; Silvane Santos; Marshall J Glesby; Edgar M Carvalho
Journal:  Clin Infect Dis       Date:  2015-03-27       Impact factor: 9.079

3.  Acoustic reflex patterns in amyotrophic lateral sclerosis.

Authors:  Andrea Canale; Roberto Albera; Michelangelo Lacilla; Antonio Canosa; Andrea Albera; Francesca Sacco; Adriano Chiò; Andrea Calvo
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-30       Impact factor: 2.503

4.  Pain in tropical spastic paraparesis/HTLV-I associated myelopathy patients.

Authors:  Carlos Maurício de Castro-Costa; Abelardo de Queiroz Campos Araújo; Carlos C Câmara; Ayrton S Ferreira; Terezinha de Jesus T Santos; Samuel Bovy de Castro-Costa; Raimundo Neudson M Alcântara; Graham P Taylor
Journal:  Arq Neuropsiquiatr       Date:  2009-09       Impact factor: 1.420

5.  Brain magnetic resonance imaging white matter lesions are frequent in HTLV-I carriers and do not discriminate from HAM/TSP.

Authors:  Daniel J Morgan; Marina F Caskey; Cristiane Abbehusen; Jamary Oliveira-Filho; Cesar Araujo; Aurelia F Porto; Silvane Braga Santos; Gloria O Orge; Maria Jose Joia; Andre L Muniz; Isadora Siqueira; Marshall J Glesby; Edgar Carvalho
Journal:  AIDS Res Hum Retroviruses       Date:  2007-12       Impact factor: 2.205

6.  Cognitive event-related potentials and brain magnetic resonance imaging in HTLV-1 associated myelopathy (HAM).

Authors:  T Fukushima; T Ikeda; E Uyama; M Uchino; H Okabe; M Ando
Journal:  J Neurol Sci       Date:  1994-10       Impact factor: 3.181

7.  Childhood-onset HAM/TSP with progressive cognitive impairment.

Authors:  Giovanna Zorzi; Roberta Mancuso; Nardo Nardocci; Laura Farina; Franca Rosa Guerini; Pasquale Ferrante
Journal:  Neurol Sci       Date:  2010-04       Impact factor: 3.307

8.  Testing the vestibular evoked myogenic potential (VEMP) to identify subclinical neurological alterations in different phases of human T-lymphotropic virus type 1 infection.

Authors:  Lilian Felipe; Herman Kingma; José R Lambertucci; Anna B Carneiro-Proietti; Denise U Gonçalves
Journal:  Spine J       Date:  2012-12-23       Impact factor: 4.166

9.  Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity.

Authors:  Tomoo Sato; Naoko Yagishita; Keiko Tamaki; Eisuke Inoue; Daisuke Hasegawa; Misako Nagasaka; Hiroko Suzuki; Natsumi Araya; Ariella Coler-Reilly; Yasuhiro Hasegawa; Yoshio Tsuboi; Ayako Takata; Yoshihisa Yamano
Journal:  Front Microbiol       Date:  2018-07-25       Impact factor: 5.640

10.  Electrophysiological analysis shows dizziness as the first symptom in human T cell lymphotropic virus type-associated myelopathy/tropical spastic paraparesis.

Authors:  Ludimila Labanca; Ana Lúcia Borges Starling; Silvio Roberto de Sousa-Pereira; Luiz Cláudio Ferreira Romanelli; Anna Bárbara de Freitas Carneiro-Proietti; Lucas Novaes Carvalho; Daniele Rosa Fernandes; Denise Utsch Gonçalves
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-16       Impact factor: 2.205

View more
  1 in total

1.  Cognitive screening in HTLV-1-infected people using a self-perceived memory score and auditory P300.

Authors:  Aline Rejane Rosa de Castro; Ludimila Labanca; Luciana Macedo de Resende; Marjore Rhaissa de Sousa; Rafael Teixeira Scoralick Dias; Júlia Fonseca de Morais Caporali; Denise Utsch-Gonçalves
Journal:  J Neurovirol       Date:  2022-02-15       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.